Skip to content

Placebo single dose

DRUG13 trials

Sponsors

Galapagos NV, Pfizer, Guangzhou Henovcom Bioscience Co. Ltd., Novartis Pharmaceuticals, Bridge Biotherapeutics, Inc.

Conditions

Cystic FibrosisHealthyHealthy ParticipantsHealthy SubjectsIgA NephropathyNASH

Phase 1

First-in-Human Single and Multiple Dose of GLPG1837
CompletedNCT02325037
Galapagos NVHealthy
Start: 2014-12-31End: 2015-09-30Updated: 2015-09-09
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
CompletedNCT02509117
PfizerHealthy Subjects
Start: 2015-07-31End: 2016-07-31Updated: 2018-11-01
First-in-Human Single and Multiple Dose of GLPG1972
CompletedNCT02612246
Galapagos NVHealthy
Start: 2015-11-30End: 2016-07-31Updated: 2016-07-29
First-in-Human Single and Multiple Dose of GLPG2222
CompletedNCT02662452
Galapagos NVHealthy
Start: 2016-01-31End: 2016-05-31Updated: 2016-07-29
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
CompletedNCT02793232
PfizerHealthy Subjects
Start: 2016-06-13End: 2017-01-05Updated: 2018-09-17
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.
CompletedNCT03128606
Galapagos NVHealthy
Start: 2017-03-28End: 2018-02-20Updated: 2018-04-10
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects
CompletedNCT03410979
Galapagos NVHealthy
Start: 2016-11-25End: 2017-08-15Updated: 2018-01-25
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
CompletedNCT03740555
Guangzhou Henovcom Bioscience Co. Ltd.Healthy
Start: 2018-11-09End: 2019-07-19Updated: 2019-09-19
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
CompletedNCT03945318
Novartis PharmaceuticalsIgA Nephropathy
Start: 2019-04-08End: 2026-06-10Updated: 2026-06-16
Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male
CompletedNCT04138849
Bridge Biotherapeutics, Inc.Healthy Participants
Start: 2019-10-01End: 2019-10-25Updated: 2020-01-18
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
CompletedNCT04926701
Enterprise Therapeutics LtdCystic Fibrosis
Start: 2021-06-11End: 2022-03-22Updated: 2022-03-24
A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants
CompletedNCT06391827
Dong-A ST Co., Ltd.Healthy
Start: 2024-05-27End: 2026-01-12Updated: 2026-05-22
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
RecruitingNCT06705998
BAR Pharmaceuticals s.r.l.NASH
Start: 2024-12-04End: 2026-07-30Target: 52Updated: 2025-09-22

Related Papers